Public Skeptical Of User Fee System, FDA Independence From Industry
This article was originally published in The Gray Sheet
Executive Summary
A recent survey suggests the public would support more robust post-approval monitoring of drugs and devices
You may also be interested in...
CDRH FY 2006 Budget Authority Would Be $165 Mil., With $56 Mil. For Field
FDA enforcement activity will receive 70% of the $6 mil. increase President Bush is requesting for the medical device program in fiscal 2006
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.